Study of the Effects of Negative Emotions on Endothelial Function

Not Applicable

Completed

• Conditions: Emotions; Endothelial Dysfunction
• Interventions: Other: Anxiety Induction; Other: Anger Induction; Other: Depressed Mood Induction; Other: Neutral emotion task

• Registration Number: NCT01909895
• Lead Sponsor: Columbia University

Brief Summary

Study aims and hypotheses are as follows:

Primary Hypotheses:

Compared to the neutral condition, the anger recall task will acutely induce endothelial dysfunction by impairing endothelium-dependent arterial vasodilation (Hypothesis 1a); increasing circulating levels of EC-derived microparticles (EMPs), a marker of EC injury (Hypothesis 1b); and reducing circulating levels of bone marrow-derived endothelial progenitor cells (EPCs), a marker of EC reparative capacity (Hypothesis 1c).

Secondary Hypotheses:

Compared to the neutral condition, the depressed mood and separately the anxiety recall tasks will acutely impair endothelium-dependent arterial vasodilation, increase circulating levels of EMPs, and reduce circulating levels of bone marrow-derived EPCs. There will be a relation of the level of self-reported anger, depressed mood, and anxiety with endothelial dysfunction.

Detailed Description

Atherosclerosis-related cardiovascular disease (CVD) events remain the leading causes of morbidity and mortality in industrialized nations. Atherosclerosis is a diffuse disease characterized by the deposition of lipid and other blood-borne material within the arterial wall. Evidence demonstrates that disruption of an arterial atherosclerotic plaque and subsequent thrombus formation is responsible for the onset of CVD events. Cardiovascular research efforts have been directed toward the identification of early underlying factors that initiate this cascade.

It has been known for some time that the experience of negative emotions is associated with an increased risk of incident CVD events, independent of traditional risk factors. Among the best-studied negative emotions is anger. Population-based studies have demonstrated that the experience of anger is a trigger of incident CVD events. The mechanism(s) by which provoked anger acutely affects the pathways that underlie atherosclerosis development and progression remain to be fully characterized.

Endothelial dysfunction is a promising mechanism that may explain the link between anger and incident CVD events. Vascular endothelial cells (ECs) play essential roles in maintaining vascular tone and the integrity of blood vessels. Evidence suggests that endothelial dysfunction is an early pathogenic process underlying atherosclerosis development and CVD event onset. Our preliminary findings show in apparently healthy individuals, an anger recall task acutely induces endothelial dysfunction by impairing endothelium-dependent vasodilation, injuring ECs, and disrupting the molecular processes underlying EC reparative capacity. We have additionally found that this task may induce endogenous nitric oxide (NO) inhibition, which plays a central role in aggravating endothelial dysfunction. Therefore, NO inhibition may partially mediate anger-provoked endothelial dysfunction.

Although the strongest data are on anger-provoked CVD events, there is also some evidence that the experience of other core negative emotions such as depressed mood and anxiety may trigger CVD events. Whether the provocation of depressed mood and anxiety acutely induces endothelial dysfunction and NO inhibition remains to be determined. The overall aim of this study is to primarily examine the acute effects of provoked anger and secondarily depressed mood and anxiety on EC health. We will also explore whether NO inhibition partially mediates the acute effects of anger, depressed mood, and anxiety on endothelial function. Examination of these critical pathways will help identify the biological pathways by which the experience of core negative emotions leads to incident CVD risk.

To address these highly significant research questions, we propose a state-of-the-art, laboratory-based, randomized controlled experiment in which 280 participants will be randomized to one of four experimental conditions: an anger recall task (N=70), a depressed mood recall task (N=70), an anxiety recall task (N=70), and an emotionally neutral condition (N=70).

Study Timeline

• Study First Submitted: 2013-07-25
• Study First Submitted QC: 2013-07-26
• Study First Posted: 2013-07-29
• Study Start: 2013-09-01
• Primary Completion: 2020-11-01
• Study Completion: 2020-11-01
• Status Verified: 2022-01
• Last Update Submitted: 2022-01-12
• Last Update Posted: 2022-01-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 280

Inclusion Criteria

• Age 18 and over
• Fluent in English

Read More

Exclusion Criteria

• History of any chronic medical condition including prevalent CVD and traditional risk factors
• Active smoking
• Chronic medication use, including over-the-counter drugs or herbal medications
• History of psychosis, a mood disorder, or any overt personality disorder
• Latex allergy
• Poor peripheral veins with low possibility of getting IV access

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Anxiety Induction	Anxiety Induction	The participant will be asked to undergo a validated anxiety induction task.
Anger induction	Anger Induction	The participant will be asked to undergo a validated anger induction task.
Depressed Mood Induction	Depressed Mood Induction	The participant will be asked to undergo a validated depression/sadness induction task.
Neutral emotion task	Neutral emotion task	The participant will be asked to undergo a validated neutral task (i.e. count aloud by ones, starting with one and ending with 100, over and over, until the task period has ended).

Primary Outcome Measures

Name	Time	Method
Endothelium-dependent arterial vasodilation	100 mins after end of mood induction
Circulating EMPs expressing CD62E	100 mins after end of mood induction
Circulating early EPCs (KDR+, CD34+, CD133+ cells)	100 mins after end of mood induction

Secondary Outcome Measures

Name	Time	Method
Circulating EMPs expressing CD31	baseline; 3 mins, 40 mins, 70 mins, 100 mins after end of mood induction
Self-reported anger, depressed mood, and anxiety	baseline; 3 mins, 40 mins, 70 mins, 100 mins after end of mood induction
Circulating EMPs expressing CD51	baseline; 3 mins, 40 mins, 70 mins, 100 mins after end of mood induction

Trial Locations

Locations (1)

Columbia University Medical Center; 🇺🇸 New York, New York, United States